Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial
PR NewswireFeb 6, 2023
- Evaluation of Bersiporocin's safety and efficacy against a total of 102 patients over 24 weeks - Development of treatment for pulmonary fibrosis which is unsatisfactory and in high demand, and anticipation for extended adaptability against various rare fibrosis diseases SEOUL, South Korea, Feb. 6, 2023 /PRNewswire/ -- The world's first-in-class candidate substance against idiopathic pulmonary fibrosis, 'Bersiposocin' (DWN12088), which is under development Daewoong Pharmaceutical, h